At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 161 enrolled
Drug / intervention
CNM-Au8 +1 moredrug
Likely dose
CNM-Au8 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HEALEY ALS Platform Trial - Regimen C CNM-Au8
In Brief
A Phase 3 clinical trial evaluating CNM-Au8 and Matching Placebo for Amyotrophic Lateral Sclerosis. Completed, enrolled 161 participants across 1 site.
Detailed Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen C will evaluate the safety and efficacy of a single study drug, CNM-Au8, in participants with ALS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
CollaboratorsClene Nanomedicine
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionApr 2022
Study CompletionMar 2023
TodayJul 2026
First PostedJun 4, 2020
Enrollment StartJul 30, 2020
Primary CompletionApr 13, 2022
Study CompletionMar 7, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.1 years ago
Interventions
CNM-Au8drug
Drug: CNM-Au8 Administration: Oral Dosage: 30 mg or 60 mg daily
Matching Placebodrug
Drug: Matching Placebo Administration: Oral Dosage: 2 bottles daily